Nexalin Reports Q2 2025: Revenue Up 163%, but Net Losses Worsen Amid Rising Operating Costs

NEXALIN TECHNOLOGY, INC. (NASDAQ: NXL) has filed its quarterly report for the period ending June 30, 2025, highlighting both opportunities and challenges within the company's financial standing and operational outlook.

Key Points and Statistics:

• Revenue Growth: Revenues increased by 163% year-over-year for Q2 2025, reaching $70,588 compared to $26,840 in Q2 2024. However, total revenue for the six-month period was $111,603, up only 6% from $105,511 in the prior year.
• Cost of Revenues: Costs of revenues significantly rose to $22,838 in Q2 from $7,247 the previous year, leading to a gross profit of $47,750, which is 68%. For the six-month period, the gross profit was $75,207, a decline from $89,108.
• Operating Expenses: Significant increase, totaling $1,668,608 in Q2 2025, compared to $1,316,614 in Q2 2024. This reflects heightened expenses in salaries, marketing, and research and development.
• Net Loss: The company reported a net loss of $1,580,987 for Q2 2025, worsening by 23% from $1,284,493 in the same quarter of the previous year. The net loss for the six months was $3,569,324, a 53% hike from $2,325,650.
• Cash Flow: Cash and cash equivalents stood at $431,320, with short-term investments at $5.36 million. The company utilized $2,343,379 in cash from operating activities over the half year.
• Accumulative Deficit: As of June 30, 2025, the accumulated deficit reached approximately $88.2 million, indicating ongoing financial struggles.
• Stockholder Equity: Stockholder equity rose to $5,963,398 from $3,676,038 due to increased capital investments.
• FDA Approval Status: The company is in active discussions with the FDA for its Gen-2 and Gen-3 devices, aimed at addressing mental health conditions.
• Joint Venture: A joint venture established to market Nexalin's devices overseas is ongoing, with no additional significant investments needed to date.

Positive Aspects:

• Strong Revenue Growth: The substantial revenue growth is a promising indicator, primarily due to successful international sales of devices and licensing agreements.
• Operating Cash Flow from Financing Activities: Significant cash was generated from stock sales, totaling $4,646,397, supporting short-term liquidity needs.

Negative Aspects:

• Increasing Operating Losses: Continuous net losses highlight the company's struggle to become profitable despite rising revenues.
• High Operating Expenses: The increase in operational costs poses concerns over future profitability, particularly in research and development and administrative expenses.
• Liquidity Risk: With negative cash flows and a significant accumulated deficit, the company's ability to sustain operations poses a concern in the short to medium term.

Outlook: Nexalin Technology is focusing on regulatory approvals for new devices while managing operational costs. The current financial metrics necessitate immediate strategic actions to ensure the sustainability of its business model.